SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
acel12067-sup-0001-DataS1-FigS1-S9-TableS1-S7.pdfapplication/PDF19151K

Data S1 Methods.

Fig. S1 Impaired neural differentiation of FOX4 shRNA H9 hESCs.

Fig. S2 FOXO4 shRNA H9 hESCs have a diminished ability to differentiate into neural cells.

Fig. S3 FOXO4 shRNA H9 hESCs have a diminished ability to differentiate into neural cells (II).

Fig. S4 FOXO4 shRNA HUES-6 hESCs have a diminished ability to differentiate into neural cells.

Fig. S5 No significant differences in PSMD11 mRNA levels between GFP OE and FOXO4 shRNA cells after neural differentiation treatment.

Fig. S6 Ectopic expression of FOXO4 AAA ameliorates the decrease ability of 3′UTR FOXO4 shRNA hESCs to differentiate into neural cells.

Fig. S7 Trophoblast differentiation.

Fig. S8 Keratinocyte differentiation.

Fig. S9 Fibroblast differentiation.

Table S1 Pluripotency marker levels in FOXO4 shRNA hESCs.

Table S3 Neural differentiation of hESCs.

Table S3 FOXO4 shRNA hESCs have a diminished ability to differentiate into neural cells.

Table S4 Trophoblast differentiation of stable FOXO4 shRNA hESCs.

Table S5 Fibroblast differentiation of stable FOXO4 shRNA hESCs.

Table S6 Expression of specific differentiation markers for ectodermal (PAX6), mesodermal (MSX1), endodermal (GATA4, GATA6, AFP) and trophectodermal (Cdx2) germ layers in hESCs prior to differentiation treatment.

Table S7 Sequences cloned to generate shRNA expressing lentiviral vectors.

acel12067-sup-0002-TableS8.xlsxapplication/msexcel12KTabls S8 List of primers used for qPCR assays

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.